Sanger Institute to extend funding for Postdoctoral Fellows affected by COVID-19 shutdown
Funding will be extended for six months, including for those funded by third parties
The Wellcome Sanger Institute will extend the contracts of all Postdoctoral Fellows (PDFs) at the Institute for six months, in light of the continuing COVID-19 shutdown. The extension includes both PDFs who are funded by the Institute directly and those funded by third parties.
The decision was taken in recognition that the shutdown of the majority of scientific operations at the Institute could impact productivity at a crucial stage for postdoctoral researchers.
“These are difficult times for many of us at the Institute for a variety of reasons and we recognise that Postdoctoral Fellows, whose funding covers a set time period, are rightly concerned about how this delay will affect them and their research. This decision makes sense for our Postdoctoral Fellows and for the Institute as a whole.”
Professor Nicole Soranzo, Chair of the Postdoctoral Fellow Development Committee
A working group has been established to oversee the extension and address any complications that may arise. This will include establishing a process to identify individuals and situations where a longer extension may be required.
“The contribution of our Postdoctoral Fellows is integral to the Institute’s scientific research. We hope that this funding extension for all our Postdoctoral Fellows will reassure them that they will be supported to complete their work once the Institute is up and running again.”
Professor Sir Mike Stratton, Director of the Wellcome Sanger Institute
If you need help or have any queries, please contact us.
Notes to Editors
21 Jan 2021
Developmental origins of eczema and psoriasis discovered
Skin Cell Atlas points to new drug targets for inflammatory diseases
18 Dec 2020
Cell atlas of tropical disease parasite may hold key to new treatments
The atlas of 13 distinct cell types at the start of the Schistosoma mansoni's development will aid vaccine and treatment ...